BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Mutations in amyloid β precursor protein (APP) gene alter APP processing, either causing familial Alzheimer9s disease (AD) or protecting against dementia. Under normal conditions, β-site APP cleaving enzyme 1 (BACE1) cleaves APP at minor Asp1 site to generate C99 for amyloid β protein (Aβ) production, and predominantly at major Glu11 site to generate C89, resulting in truncated Aβ production. We discovered that A673V mutation, the only recessive AD-associated APP mutation, shifted the preferential β-cleavage site of BACE1 in APP from the Glu11 site to the Asp1 site both in male and female transgenic mice in vivo and in cell lines and primary neuronal culture derived from timed pregnant rats in vitro, resulting in a much higher C99 level and C99/C89 ratio. All other mutations at this site, including the protective Icelandic A673T mutation, reduced C99 generation, and decreased the C99/C89 ratio. Furthermore, A673V mutation caused stronger dimerization between mutant and wild-type APP, enhanced the lysosomal degradation of the mutant APP, and inhibited γ-secretase cleavage of the mutant C99 to generate Aβ, leading to recessively inherited AD. The results demonstrate that APP673 regulates APP processing and the BACE1 cleavage site selection is critical for amyloidogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site for AD drug development. SIGNIFICANCE STATEMENT β-site APP cleaving enzyme 1 (BACE1) is essential for amyloid β protein production. We discovered that A673V mutation shifted the BACE1 cleavage site from the Glu11 to the Asp1 site, resulting in much higher C99 level and C99/C89 ratio. All other mutations at this site of amyloid β precursor protein (APP) reduced C99 generation and decreased the C99/C89 ratio. Furthermore, A673V mutation resulted in stronger dimerization between mutant and wild-type APP, enhanced the lysosomal degradation of the mutant APP, and inhibited γ-secretase cleavage of the mutant C99 to generate amyloid β protein, leading to recessively inherited Alzheimer9s disease (AD). The results demonstrate that APP673 regulates APP processing, and the BACE1 cleavage site selection is critical for amyloidogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site for AD drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 3×
“, 2007), increasing A 42 level or the ratio of A 42 to A 40 (London mutation V717I and Florida mutation I716V) (Goate et al., 1991; Eckman et al., 1997; De Jonghe et al., 2001), or accelerating A 40 fibril formation (Dutch mutation E693Q and Iowa mutation D694N) (Wisniewski et al.”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 3×
“…missense mutation of alanine to threonine on the same residue (A673T) in the Icelandic population, in contrast, was protective against AD development (Jonsson et al., 2012), suggesting that the amino acid at position 673 of APP might be critical for BACE1 cleavage site selection for APP processing.”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 5×
“These mutations have been shown to cause FAD by altering APP processing, including enhancing C99 production (Swedish mutation KM670/671NL) (Mullan et al., 1992; Felsenstein et al., 1994; Perez et al., 1996), inhibiting nonamyloidogenic -cleavage of APP (Arctic mutation E693G) (Nilsberth et al.,…”
BackgroundInfluentialThe 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 3×
“, 1996), inhibiting nonamyloidogenic -cleavage of APP (Arctic mutation E693G) (Nilsberth et al., 2001; Stenh et al., 2002; Sahlin et al., 2007), increasing A 42 level or the ratio of A 42 to A 40 (London mutation V717I and Florida mutation I716V) (Goate et al.”
BackgroundHypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 1×
“…cleavage of APP or shifting its preferential cleavage site from Glu 11 to Asp 1 resulted in higher C99 and A production and hence facilitated neuritic plaque formation under pathological conditions (Mullan et al., 1992; Sun et al., 2006a, b; Deng et al., 2013; Ly et al., 2013; Zhang et al., 2014).”
BackgroundSelf-citationInhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442 · cited 3×
“Enhancing BACE1 cleavage of APP or shifting its preferential cleavage site from Glu 11 to Asp 1 resulted in higher C99 and A production and hence facilitated neuritic plaque formation under pathological conditions (Mullan et al., 1992; Sun et al., 2006a, b; Deng et al., 2013; Ly et al., 2013; Zhang et al., 2014).”
BackgroundMethodSelf-citationSong, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., & Yankner, B. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6959 · Cited by 362 · cited 1×
“C83 is subsequently cleaved by -secretase to generate CTF and p3 fragment, precluding A production (Song et al., 1999; Zhang et al., 2000; Qing et al., 2008).”
BackgroundSelf-citationAmino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro
Pike, C. J., Overman, M. J., & Cotman, C. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23895 · Cited by 302
A New Pathogenic Mutation in the APP Gene (I716V) Increases the Relative Proportion of A 42(43)
Eckman, C. B., Mehta, N. D., Crook, R., Perez-tur, J., Prihar, G., Pfeiffer, E., Graff-Radford, N., Hinder, P., Yager, D., Zenk, B., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2087 · Cited by 236
De Jonghe, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1665 · Cited by 223 · cited 1×
“…increasing A 42 level or the ratio of A 42 to A 40 (London mutation V717I and Florida mutation I716V) (Goate et al., 1991; Eckman et al., 1997; De Jonghe et al., 2001), or accelerating A 40 fibril formation (Dutch mutation E693Q and Iowa mutation D694N) (Wisniewski et al., 1991; Van Nostrand et…”
BackgroundDeng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108 · cited 6×
“…cleavage of APP or shifting its preferential cleavage site from Glu 11 to Asp 1 resulted in higher C99 and A production and hence facilitated neuritic plaque formation under pathological conditions (Mullan et al., 1992; Sun et al., 2006a, b; Deng et al., 2013; Ly et al., 2013; Zhang et al., 2014).”
BackgroundInfluentialSelf-citationFelsenstein, K. M., Hunihan, L. W., & Roberts, S. B. (1994) · Nature Genetics · doi:10.1038/ng0394-251 · Cited by 90 · cited 3×
“These mutations have been shown to cause FAD by altering APP processing, including enhancing C99 production (Swedish mutation KM670/671NL) (Mullan et al., 1992; Felsenstein et al., 1994; Perez et al., 1996), inhibiting nonamyloidogenic -cleavage of APP (Arctic mutation E693G) (Nilsberth et al.”
BackgroundNeuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features
Giaccone, G., Morbin, M., Moda, F., Botta, M., Mazzoleni, G., Uggetti, A., Catania, M., Moro, M. L., Redaelli, V., Spagnoli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0747-1 · Cited by 73 · cited 1×
“By contrast, the homozygous proband developed dementia symptoms by the age of 36 and died at 46, and his homozygous sister also showed mild cognitive impairment (Giaccone et al., 2010).”
BackgroundPeacock, M. L., Warren, J. T., Roses, A. D., & Fink, J. K. (1993) · Neurology · doi:10.1212/wnl.43.6.1254 · Cited by 66
Cited by
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“The beta site APP cleaving enzyme 1 (BACE1), the β-secretase, and its homolog BACE2, the θ-secretase, also contribute to the non-amyloidogenic pathway.(7,8) Under physiological conditions, BACE1 predominantly processes APP at the Aβ Glu(11) β-secretase site to generate C89, and γ-secretase cleaves C89 to produce a tru…”
BackgroundSelf-citationBrain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Self-citationOxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics
Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 275
Griñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease
Wang, X., Zhou, X., Li, G., Zhang, Y., Wu, Y., & Song, W. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00294 · Cited by 172
Self-citation
Metadata
- Authors
- Zhang, S., Wang, Z., Cai, F., Zhang, M., Wu, Y., Zhang, J., & Song, W.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-06-16
- Volume
- 37
- Issue
- 29
- Pages
- 6915-6925
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2624778884
- Cited by
- 129
- References
- 14
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.